Medication middlemen face bipartisan criticism as Congress eyes industry reforms

Executives from three of the largest pharmacy benefit managers (PBMs) pushed back against bipartisan criticism during a House Oversight Committee hearing Tuesday where lawmakers faulted the industry for high drug prices. The executives blamed drug companies for those prices, saying PBMs save patients money, and that customers actively choose to partner with them because of...